These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 18215509)

  • 1. A pharmacokinetic/pharmacodynamic mathematical model accurately describes the activity of voriconazole against Candida spp. in vitro.
    Li Y; Nguyen MH; Cheng S; Schmidt S; Zhong L; Derendorf H; Clancy CJ
    Int J Antimicrob Agents; 2008 Apr; 31(4):369-74. PubMed ID: 18215509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic/pharmacodynamic modelling and in vitro simulation of dynamic voriconazole-Candida interactions.
    Li Y; Nguyen MH; Schmidt S; Zhong L; Derendorf H; Clancy CJ
    Int J Antimicrob Agents; 2009 Sep; 34(3):240-5. PubMed ID: 19339162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.
    Andes D; Marchillo K; Stamstad T; Conklin R
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3165-9. PubMed ID: 14506026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography.
    Li Y; Nguyen MH; Derendorf H; Cheng S; Clancy CJ
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2985-7. PubMed ID: 17517840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection.
    Lewis RE; Kontoyiannis DP; Darouiche RO; Raad II; Prince RA
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3499-505. PubMed ID: 12384356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of voriconazole pharmacodynamics using time-kill methodology.
    Klepser ME; Malone D; Lewis RE; Ernst EJ; Pfaller MA
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1917-20. PubMed ID: 10858354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new in-vitro kinetic model to study the pharmacodynamics of antifungal agents: inhibition of the fungicidal activity of amphotericin B against Candida albicans by voriconazole.
    Lignell A; Johansson A; Löwdin E; Cars O; Sjölin J
    Clin Microbiol Infect; 2007 Jun; 13(6):613-9. PubMed ID: 17378925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential fungicidal effect of voriconazole against Candida spp.
    Rubio MC; de Ocáriz IR; Gil J; Benito R; Rezusta A
    Int J Antimicrob Agents; 2005 Mar; 25(3):264-7. PubMed ID: 15737524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
    Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
    Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic/Pharmacodynamic Analysis of Isavuconazole Against Aspergillus spp. and Candida spp. in Healthy Subjects and Patients With Hepatic or Renal Impairment by Monte Carlo Simulation.
    Zheng X; Xu G; Zhu L; Fang L; Zhang Y; Ding H; Tong Y; Sun J; Huang P
    J Clin Pharmacol; 2018 Oct; 58(10):1266-1273. PubMed ID: 29762861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the inhibitory effect of voriconazole on the fungicidal activity of amphotericin B against Candida albicans in an in vitro kinetic model.
    Lignell A; Löwdin E; Cars O; Sjölin J
    J Antimicrob Chemother; 2008 Jul; 62(1):142-8. PubMed ID: 18408237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro pharmacokinetic/pharmacodynamic modeling of voriconazole activity against Aspergillus species in a new in vitro dynamic model.
    Al-Saigh R; Elefanti A; Velegraki A; Zerva L; Meletiadis J
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5321-7. PubMed ID: 22869563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voriconazole efficacy against Candida glabrata and Candida krusei: preclinical data using a validated in vitro pharmacokinetic/pharmacodynamic model.
    Beredaki MI; Georgiou PC; Siopi M; Kanioura L; Arendrup MC; Mouton JW; Meletiadis J
    J Antimicrob Chemother; 2020 Jan; 75(1):140-148. PubMed ID: 31665417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of voriconazole against Candida species.
    Kauffman CA; Zarins LT
    Diagn Microbiol Infect Dis; 1998 May; 31(1):297-300. PubMed ID: 9597390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.
    Nguyen MH; Yu CY
    J Antimicrob Chemother; 1998 Aug; 42(2):253-6. PubMed ID: 9738846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain.
    Cuenca-Estrella M; Díaz-Guerra TM; Mellado E; Monzón A; Rodríguez-Tudela JL
    Eur J Clin Microbiol Infect Dis; 1999 Jun; 18(6):432-5. PubMed ID: 10442422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
    Marco F; Pfaller MA; Messer S; Jones RN
    Antimicrob Agents Chemother; 1998 Jan; 42(1):161-3. PubMed ID: 9449278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.
    Di Bonaventura G; Spedicato I; Picciani C; D'Antonio D; Piccolomini R
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4453-6. PubMed ID: 15504881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of voriconazole against Candida species isolated in Taiwan.
    Yang YL; Cheng HH; Lo HJ
    Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voriconazole and fluconazole susceptibility of Candida isolates.
    Pelletier R; Loranger L; Marcotte H; DE Carolis E
    J Med Microbiol; 2002 Jun; 51(6):479-483. PubMed ID: 12018654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.